Patients with non-small cell lung cancer, also known as NSCLC, are anxiously awaiting a decision from the FDA’s Oncologic Drugs Advisory Committee regarding Eli Lilly’s introduction of Necitumumab to the already formidable Gemcitabine and Cisplatin combination. Both Gemcitabine and Cisplatin are currently the first line-treatment for patients diagnosed with NSCLC, and the addition of Necitumumab[…]
Gemcitabine and Cisplatin Continue as Successful Therapy for Patients with NSCLC
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, OTC and Compounding Product Tags: EGFR Aug 11, 2015
Progression Free Survival Goal Met With Cobimetinib
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: EGFRmelanoma Aug 11, 2014
Impressive news was revealed from Roche and Exelixis on June 14, 2014 with successful Phase III study results from their melanoma trial. This comprehensive trial involved Exelixis’s Cobimetinib and Zelboraf, which is marketed by Roche, for treating patients with advanced cases of melanoma. All of the 495 patients had specific mutations of the BRAF gene[…]
Pancreatic Cancer Predicted to Become the Second Cause of U.S. Cancer Deaths
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: EGFRPaclitaxel Jun 19, 2014
Startling news emerged on May 19, 2014 with an ominous report issued from the Pancreatic Cancer Action Network. The report has predicted that pancreatic cancer will become the #2 cause of cancer deaths in the year 2030, bumping colorectal cancer to the third slot. This sobering information comes in response to recent changes in American[…]
EU Approves Cabozantinib for Metastatic Medullary Thyroid Carcinoma
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, EU Approved 2014 Tags: EGFREU Apr 17, 2014
The end of March 2014 brought exciting news from the EU with the announcement of their approval of Cabozantinib for unresectable medullary thyroid carcinoma. Known as the brand name Cometriq and marketed by Exelixis, Cabozantinib works by inhibiting the activity of MET, RET and VEGFR tyrosine kinases. Cases of medullary thyroid carcinoma are virulent and[…]
Regorafenib Tablet Gains EU Approval for Colorectal Cancer Treatment
Chemotherapeutic / Anti-Neoplastic, EU Approved 2013 Tags: EGFREUregorafenib Sep 03, 2013
The Regorafenib tablet gains EU approval for the treatment of metastasized colorectal cancer (mCRC) in adults, whose disease has progressed even after treatment with standard drugs. Regorafenib was previously approved by the FDA in late May 2012 to treat patients with metastatic colorectal cancer. That initial approval of Regorafenib for unresectable colon cancer was based on the[…]
Monoclonal Antibodies (mAbs) – Growth, Supply, and Uses for Cancer Treatment
Antithrombotic, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: 180288-69-1331731-18-1AdalimumabAlemtuzumabBevacizumabchemotherapyEGFRRituximabTrastuzumab Feb 11, 2011
What Are Monoclonal Antibodies? A monoclonal antibody is a laboratory-produced molecule that’s carefully engineered to attach to specific defects in your cancer cells. Monoclonal antibodies mimic the antibodies your body naturally produces as part of your immune system’s response to germs, vaccines and other invaders. Growing Interest for Monoclonal Antibody Therapies Monoclonal antibodies were initially[…]
